MBX Biosciences Management
Management criteria checks 0/4
MBX Biosciences' CEO is Peter Hawryluk, appointed in Jan 2020, has a tenure of 4.83 years. total yearly compensation is $4.86M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 2.63% of the company’s shares, worth $16.27M. The average tenure of the management team and the board of directors is 1.4 years and 2.6 years respectively.
Key information
Peter Hawryluk
Chief executive officer
US$4.9m
Total compensation
| CEO salary percentage | 8.6% |
| CEO tenure | 4.8yrs |
| CEO ownership | 2.6% |
| Management average tenure | 1.4yrs |
| Board average tenure | 2.6yrs |
Recent management updates
No updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$55m |
| Jun 30 2024 | n/a | n/a | -US$47m |
| Mar 31 2024 | n/a | n/a | -US$39m |
| Dec 31 2023 | US$5m | US$420k | -US$33m |
Compensation vs Market: Peter's total compensation ($USD4.86M) is above average for companies of similar size in the US market ($USD3.17M).
Compensation vs Earnings: Insufficient data to compare Peter's compensation with company performance.
CEO
Peter Hawryluk (55 yo)
4.8yrs
Tenure
US$4,862,064
Compensation
Mr. P. Kent Hawryluk, MBA, served as Chief Business Officer of Avidity Biosciences LLC from January 2013 to December 19, 2019. Mr. Hawryluk is a Partner at Twilight Venture Partners, LLC. He co-founded and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.8yrs | US$4.86m | 2.63% $ 16.3m | |
| Chief Financial Officer | 2.6yrs | US$1.05m | 0% $ 0 | |
| Chief Scientific Officer | 1.3yrs | no data | no data | |
| Vice President of Marketing | 1.5yrs | no data | no data | |
| Chief Human Resources Officer | 1.1yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
1.4yrs
Average Tenure
57yo
Average Age
Experienced Management: MBX's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.6yrs | US$4.86m | 2.63% $ 16.3m | |
| Independent Director | 4.3yrs | no data | no data | |
| Independent Director | 4.3yrs | no data | no data | |
| Independent Director | 4.1yrs | no data | 0.31% $ 1.9m | |
| Independent Director | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 2.6yrs | no data | 0.050% $ 307.8k | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 2yrs | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data |
2.6yrs
Average Tenure
64yo
Average Age
Experienced Board: MBX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.